Trials / Conditions / Unresectable Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

11 registered clinical trials studyying Unresectable Intrahepatic Cholangiocarcinoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intra NCT06058663	Mayo Clinic	Phase 1
Active Not Recruiting	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A Co NCT05564403	National Cancer Institute (NCI)	Phase 2
Unknown	Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrah NCT05738057	Hua Li	Phase 2
Completed	Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcino NCT04301778	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2
Active Not Recruiting	mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for NCT04251715	OHSU Knight Cancer Institute	Phase 2
Active Not Recruiting	Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver NCT04175912	National Cancer Institute (NCI)	Phase 2
Recruiting	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inh NCT03942328	Mayo Clinic	Phase 1 / Phase 2
Completed	Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnos NCT03768414	SWOG Cancer Research Network	Phase 3
Terminated	A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients NCT02994251	Yale University	Phase 2
Terminated	A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectabl NCT02256982	Massachusetts General Hospital	N/A
Completed	Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabi NCT01648023	Robert C. Martin	Phase 2